NCT00671814View on ClinicalTrials.gov

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 6, 2008

Primary Completion Date

June 6, 2008

Study Completion Date

June 6, 2008

Conditions
Healthy Subjects
Interventions
DRUG

TR-701

TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.

DRUG

linezolid

Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.

DRUG

placebo

Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

All Listed Sponsors
lead

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00671814 - Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults | Biotech Hunter | Biotech Hunter